Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Orchestra BioMed Holdings, Inc. - Ordinary Shares (NQ:OBIO)

4.190 -0.020 (-0.48%)
Streaming Delayed Price Updated: 12:44 PM EDT, Apr 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Orchestra BioMed Holdings, Inc. - Ordinary Shares

< Previous 1 2 3 Next >
News headline image
Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Host Business Update Call on November 12, 2025
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Pricing of $40 Million Public Offering
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Proposed Public Offering
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Sidoti Events, LLC's Virtual May Micro-Cap Conference
Via ACCESS Newswire
News headline image
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.